Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Dividend Updates
The Board at its Meeting held today recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. Supriya Lifescience Ltd - 543434 - Board recommends Final Dividend
Supriya Lifescience Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 20, 2022, inter alia, has recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. Supriya Lifescience Ltd - 543434 - Audited Financial Results For The Quarter And Year Ended March 31, 2022
Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 20, 2022, inter-alia, has: 1. Considered and approved the Audited Financial Results for the Quarter and year ended March 31, 2022. 2. Recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, May 20, 2022, inter-alia, has: 1. Considered and approved the Audited Financial Results for the Quarter and year ended March 31, 2022. 2. Recommended the Final Dividend of Rs. 0.60 per equity share (face value of Rs. 2/- each) subject to approval of shareholders in the ensuing Annual General Meeting. The Financials Results will be published in newspapers as required under the Listing Regulations. The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 04:30 p.m. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Monday, May 23, 2022 at 3.30 P.M. IST to discuss operational and financial performance of the Company for the fourth quarter and year ended March 31, 2022. The invite giving requisite details including the pre-registration link and dial-in details is attached herewith. This intimation is also being made available on the website of the Company at: https://supriyalifescience.com/investor-relation/ Kindly take the information on record. Supriya Lifescience Ltd - 543434 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Supriya Lifescience Ltd 2 CIN NO. L51900MH2008PLC180452 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-2022, 2022-2023 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NIL Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Shweta SinghDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Ashish Nayak Designation : -Chief Financial Officer Date: 14/05/2022 Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report dated May 13, 2022 issued by ICICI Bank Limited, Monitoring Agency, for the quarter ended March 31, 2022 in respect of utilization of proceeds of the of the fresh issue of the IPO of the Company. Kindly take the same on record and acknowledge the receipt. Supriya Lifescience Ltd - 543434 - European Directorate For The Quality Of Medicines & Healthcare (EDQM), France And Italian Medicines Agency (AIFA), Italy Completes Joint Audit Of Lote API Facility, Ratnagiri, Maharashtra
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that we have concluded joint audit of EDQM, France & AIFA, Italy in the above API facility during the period from May 9, 2022 to May 13, 2022 successfully. This is for your information and records. Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2022 And To Recommend Dividend, If Any, For The Financial Year Ended March 31, 2022
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2022 and to recommend dividend, if any, for the financial year ended March 31, 2022. This is further to inform you that with reference to our letter dated March 30, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Audited Financial Results for the quarter and year months ended March 31, 2022. Kindly take the above said information on your records.